Retatrutide vs tirzepatide vs semaglutide: receptors, structure and research status

Retatrutide, tirzepatide and semaglutide belong to the same family of incretin peptides. Each one binds receptors that model systems use to study post-meal signalling and glucose homeostasis. They differ in how many receptors they engage, how the molecule is built and how far each one has progressed in research. This guide lays those differences out in a form you can scan before planning an experiment. All three compounds are sold as research use only reagents. For a wider view of the family, browse our incretin analogues for research collection.

From one receptor to three

The simplest way to compare them is by the number of molecular targets. Semaglutide acts on one receptor, tirzepatide on two and retatrutide on three. Each added receptor is an extra signalling pathway that researchers can study on its own, which helps isolate the contribution of each one to an observed effect.

The GLP-1 receptor

GLP-1 is a hormone released in the gut after a meal. In cell and animal models, its receptor takes part in glucose-dependent insulin secretion and in signalling that affects how quickly the stomach empties. Semaglutide is an agonist of this receptor, meaning it activates it.

The GIP receptor

GIP is the second incretin hormone in this family. Tirzepatide is a dual agonist because it activates GIP and GLP-1 receptors at the same time. Studies of glucose homeostasis often compare the effects of GLP-1 signalling alone with the combined signalling of GIP and GLP-1.

The glucagon receptor

Glucagon works in the opposite direction to insulin, raising blood glucose. Its receptor is also studied in the context of energy expenditure and lipid metabolism. Retatrutide combines three signals, GIP, GLP-1 and glucagon, which is why the literature describes it as a triple agonist.

Side-by-side comparison

Parameter	Retatrutide	Tirzepatide	Semaglutide
Receptors	GIP, GLP-1, glucagon	GIP, GLP-1	GLP-1
Mode of action	triple agonist	dual agonist	GLP-1 agonist
Peptide chain length	about 39 residues	39 residues	31 residues
Molecular modification	lipid chain	C20 fatty acid chain	fatty acid chain that binds albumin
Molecular mass	4731.3 Da	4813.5 Da	4113.6 Da
Molecular formula	C221H342N46O68	C225H348N48O68	C187H291N45O59
Half-life (from published data)	about 6 days	about 5 days	about 7 days
Status	in phase 2 and 3 clinical programme	registered medicine	registered medicines
CAS number	2381089-83-2	2023788-19-2	910463-68-2

Masses and formulas come from the product data sheets. Every batch is checked by MS, so the mass can be matched against this table.

Structure: peptide plus fatty chain

All three compounds are synthetic analogues of incretin peptides. Natural hormones are short and break down quickly, which is why research uses modified molecules. The key change is attaching a fatty acid or lipid chain. That chain binds albumin (a plasma protein) and extends the period during which the molecule stays active in models.

Semaglutide has 31 amino acid residues, while tirzepatide and retatrutide have about 39. A longer peptide chain combined with a different modification gives each molecule its own physicochemical profile. For a lab, that means different handling and analysis requirements, even when the receptor mechanism looks similar.

Half-life: what the data show

Half-life is the time it takes for the concentration of a substance to fall by half. In published data, semaglutide has the longest half-life, around one week. Tirzepatide lasts about 5 days, and retatrutide about 6 days in clinical reports. The differences come from the structure of the fatty chain and how the molecule binds albumin.

For a researcher, this parameter matters when designing a time-course experiment, for example when setting a schedule for sample collection. It is a tool for planning a study, not guidance for use in people.

Status: approved medicine, clinical study or reagent

Each compound has a different status, and it is worth knowing it before you choose a material:

• Semaglutide is the substance of registered medicines and one of the most widely described GLP-1 analogues in the literature, including clinical studies.
• Tirzepatide is a registered medicine and has been the subject of many clinical programmes.
• Retatrutide is in a phase 2 and 3 clinical programme. It is not registered as a medicine.

Clinical studies have described effects of these compounds on body mass and glycaemia. Those results come from published papers and describe a specific study, not a guaranteed outcome in any other setting.

What is studied in models

Comparing three molecules is useful because it helps separate the effect of each receptor. Typical lines of inquiry include:

• receptor signalling in cell lines, comparing GLP-1, GIP and glucagon,
• glucose homeostasis and insulin secretion in animal models,
• lipid metabolism and body mass in animal models,
• selective agonists compared with multi-receptor agonists.

This kind of design shows which effects come from a single pathway and which arise from combined signalling.

Working in the lab

All three products are lyophilised, meaning they arrive as a powder in a vial. Store them cold, away from light and moisture, and reconstitute them according to your laboratory protocol. The working concentration is set by the researcher within their own project. Before starting, check that the batch HPLC purity and MS mass match the product data sheet.

Good practice is to record the batch number, the date the vial was opened and the storage conditions. That way, results can be reproduced and compared later.

Why buy from MOLEVIA

MOLEVIA supplies retatrutide, tirzepatide and semaglutide for research on the following terms:

• purity of 99% or higher (HPLC) and mass confirmed by MS,
• orders placed by 14:00 on a business day ship the same day,
• InPost Paczkomat in Poland: next business day delivery, and DPD in Europe in 2-4 business days, with shipping to 29 European countries,
• free shipping from 75 EUR, 65 GBP, 80 USD,
• automatic volume discount: 5% for 2 pieces, 10% for 3 pieces, 15% for 5 pieces,
• 10 ml bacteriostatic water free with orders from 50 EUR that include a peptide vial,
• Pay online by card, Apple Pay, Google Pay or BLIK (PLN only).

You can find the products from this comparison here: Retatrutide, Tirzepatide and Semaglutide. The full list of incretin analogues is in the category incretin analogues.

Key takeaways

• Semaglutide is a GLP-1 agonist with the longest half-life in published data and the status of registered medicines.
• Tirzepatide is a dual GIP and GLP-1 agonist and a registered medicine.
• Retatrutide is a triple agonist of GIP, GLP-1 and glucagon, in a phase 2 and 3 clinical programme.
• The differences come from the number of receptors, the length of the peptide chain and the fatty modification.
• Every MOLEVIA batch comes with purity of 99% or higher and a confirmed MS mass.